Transcatheter Aortic Valve Replacement (TAVR) Clinical Trials

Clinical trials related to Transcatheter Aortic Valve Replacement (TAVR) Procedure

Impact of Beta-blocker Continuation Versus Interruption in Patients Undergoing Transcatheter Aortic Valve Implantation

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The BETA-TAVI trial is a prospective, investigator-initiated, multicenter, randomized, open-label, non-inferiority trial designed to evaluate the safety of continuing versus temporarily interrupting chronic beta-blocker therapy in patients undergoing transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis. A total of 348 patients receiving chronic oral beta-blocker therapy will be randomized in a 1:1 ratio to either continuation of their prescribed beta-blocker from at least 72 hours before TAVI through 7 days after the procedure or temporary interruption of beta-blocker therapy during the same period. Treatment modifications will be permitted when clinically indicated. The primary objective is to determine whether beta-blocker continuation is non-inferior to interruption regarding the incidence of new permanent pacemaker implantation within 7 days after TAVI, using an absolute non-inferiority margin of 6.5 percentage points. Secondary outcomes include atrioventricular conduction disturbances, atrial and ventricular arrhythmias, hemodynamic deterioration, subsequent permanent pacemaker implantation, and all-cause and cardiovascular mortality. Clinical follow-up will be performed at discharge, 7 days, 30 days, and 12 months after TAVI.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Current oral beta-blocker treatment for a recognized clinical indication. Ability and willingness to comply with the assigned treatment strategy and follow-up schedule.

• Written informed consent before any trial-specific procedure.

Locations
Other Locations
Cyprus
Nicosia General Hospital
RECRUITING
Nicosia
Greece
First Department of Cardiology, National and Kapodistrian University of Athens
RECRUITING
Athens
Contact Information
Primary
Leonidas Koliastasis, MD, MSc, PhD
lkoliastasis@gmail.com
6974270752
Backup
Odysseas Katsaros, MD
odykatsaros@gmail.com
+306944362412
Time Frame
Start Date: 2024-06-01
Estimated Completion Date: 2028-01-31
Participants
Target number of participants: 348
Treatments
Active_comparator: Beta-blockers continuation
Patients assigned in the beta-blockers continuation arm will be receiving per os beta blocker medication for at least 72 hours before TAVI without interruption after it.
Active_comparator: Beta-blockers interruption
Patients assigned to interrupt the beta-blockers treatment will abstain from beta blockers for at least 7 days after TAVI.
Sponsors
Leads: National and Kapodistrian University of Athens
Collaborators: Evangelismos Hospital, Interbalkan Medical Center, Thessaloniki, Greece

This content was sourced from clinicaltrials.gov